Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression.

Dinesh Khanna,Toby M Maher,Elizabeth R Volkmann,Yannick Allanore,Vanessa Smith,Shervin Assassi,Michael Kreuter,Anna-Maria Hoffmann-Vold,Masataka Kuwana,Christian Stock,Margarida Alves,Steven Sambevski,Christopher P Denton

RMD open（2023）

引用 1|浏览22

暂无评分

摘要

In the SENSCIS trial, subjects with SSc-ILD who had early SSc, elevated inflammatory markers or extensive skin fibrosis had a more rapid decline in FVC over 52 weeks than the overall trial population. Nintedanib had a numerically greater effect in patients with these risk factors for rapid ILD progression.

查看译文

关键词

Autoimmune Diseases,Pulmonary Fibrosis,Scleroderma, Systemic,Therapeutics

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要